Charles Schwab
SRNE

Charles Schwab’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Charles Schwab’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,508,377
Closed -$3.11M – 3627
2022
Q4 		$3.11M Buy
3,508,377
+674,716
+24% +$895K ﹤0.01% 2422
2022
Q3 		$4.45M Buy
2,833,661
+66,757
+2% +$151K ﹤0.01% 2269
2022
Q2 		$5.56M Buy
2,766,904
+565,217
+26% +$977K ﹤0.01% 2142
2022
Q1 		$5.13M Buy
2,201,687
+58,593
+3% +$183K ﹤0.01% 2267
2021
Q4 		$9.97M Buy
2,143,094
+110,344
+5% +$685K ﹤0.01% 2008
2021
Q3 		$15.5M Buy
2,032,750
+302,190
+17% +$2.56M 0.01% 1765
2021
Q2 		$16.8M Buy
1,730,560
+91,306
+6% +$727K 0.01% 1709
2021
Q1 		$13.6M Buy
1,639,254
+116,705
+8% +$1.23M 0.01% 1782
2020
Q4 		$10.4M Buy
1,522,549
+152,480
+11% +$1.22M ﹤0.01% 1851
2020
Q3 		$15.3M Buy
1,370,069
+927,446
+210% +$8.49M 0.01% 1395
2020
Q2 		$2.78M Buy
442,623
+117,131
+36% +$448K ﹤0.01% 2299
2020
Q1 		$599K Buy
325,492
+8,463
+3% +$24.4K ﹤0.01% 2653
2019
Q4 		$1.07M Buy
317,029
+23,894
+8% +$57K ﹤0.01% 2575
2019
Q3 		$628K Buy
293,135
+18,689
+7% +$43.6K ﹤0.01% 2715
2019
Q2 		$733K Buy
274,446
+40,192
+17% +$145K ﹤0.01% 2679
2019
Q1 		$1.11M Sell
234,254
-38,411
-14% -$101K ﹤0.01% 2521
2018
Q4 		$655K Buy
272,665
+35,590
+15% +$116K ﹤0.01% 2669
2018
Q3 		$1.04M Buy
237,075
+57,136
+32% +$317K ﹤0.01% 2612
2018
Q2 		$1.3M Buy
179,939
+162,000
+903% +$1.1M ﹤0.01% 2506
2018
Q1 		$93K Buy
+17,939
New +$128K ﹤0.01% 3046
2017
Q2 		– Sell
-39,855
Closed -$158K – 3156
2017
Q1 		$158K Hold
39,855
– – ﹤0.01% 2964
2016
Q4 		$196K Hold
39,855
– – ﹤0.01% 2967
2016
Q3 		$309K Hold
39,855
– – ﹤0.01% 2785
2016
Q2 		$224K Hold
39,855
– – ﹤0.01% 2895
2016
Q1 		$215K Hold
39,855
– – ﹤0.01% 2880
2015
Q4 		$348K Hold
39,855
– – ﹤0.01% 2804
2015
Q3 		$335K Sell
39,855
-1,100
-3% -$17.5K ﹤0.01% 2781
2015
Q2 		$722K Buy
+40,955
New +$526K ﹤0.01% 2548

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Charles Schwab's SRNE Position: Q1 2023 in Review

Charles Schwab sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 3,508,377 shares — an estimated $3.11M sold.

Charles Schwab first reported a position in SRNE in Q2 2015 and held it in 28 quarters. The position peaked at $16.8M in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Charles Schwab reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Charles Schwab sold 3,508,377 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $3.11M.
  • Charles Schwab first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 28 quarters.
  • Charles Schwab's Sorrento Therapeutics, Inc. position peaked at $16.8M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.